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Hydroxamic acidAbstract A series of novel 50(70)-substituted-20-oxospiro[1,3]dioxolane-2,30-indoline-based
N-hydroxypropenamides were designed, synthesized and evaluated for histone deacetylase (HDAC)
inhibition and cytotoxicity. It was found that the compounds in this series displayed potent inhibi-
tory effects against HDAC2 with IC50 values as low as 0.284 lM, almost comparable to that of
SAHA (IC50, 0.265 lM), a positive control. In Western blot analysis, these compounds also exhib-
ited noted inhibition toward histone deacetylation and this inhibition was found to correlate well
with the cytotoxicity of the compounds in three human cancer cell lines. Docking studies indicated
the compounds in this series bound to HDAC2 with high binding afﬁnities (9.8 kcal/mol) com-
pared to SAHA (7.4 kcal/mol).
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Since histone deacetylases (HDACs) are found to get involved
in the regulation of cell-cycle progression and carcinogenic
process (Ropero and Esteller, 2007; Archer and Hodint,
1999), these enzymes have become attractive targets for anti-
cancer drug discovery. Currently, 18 mammalian HDACs have
been identiﬁed and the HDACs can be divided into four mainnamides
2 D.T.M. Dung et al.classes according to their homology to yeast HDACs (De
Ruijter et al., 2003). Class I consists of HDAC 1, 2, 3, 8, class
II consists of HDAC 4, 5, 6, 7, 9, 10 and class IV contains only
one member, HDAC 11. All members of classes I, II and IV
are known as ‘‘classical” HDACs and are Zn2+-dependent
enzymes. The class III called Sirtuins (SIRT1–7) and the
enzyme of this class are NAD+-dependent enzymes
(Giannini et al., 2012).
Thousands of HDAC inhibitors with diverse structural fea-
tures have been either isolated or synthesized. Many of these
have been shown to exert very potent bioactivities, not only
in terms of HDAC inhibition, but also in terms of cytotoxicity
against human cancer cell lines. A dozen of compounds, such
as suberoylanilide hydroxamic acid (SAHA, Vorinostat),
LBH-589 (Panobinostat), MS-27-527 (Entinostat), PXD-01
(Belinostat), and romidepsin (Fig. 1), have been proved to be
promising in both preclinical and clinical trials (Giannini
et al., 2012; Kim et al., 2011). Two ﬁrst HDAC inhibitors,
including SAHA (suberoylanilide hydroxamic acid, trade
name, Zolinza) and romidepsin (tradename, Istodax)
(Fig. 1) have been approved by the US FDA in 2006 and
2009, respectively, to treat cutaneous T-cell lymphoma
(Giannini et al. 2012; Kim et al., 2011). More recently, PXD-
01 (Belinostat, trade name Beleodaq) and LBH-589 (Panobi-
nostat, trade name Farydak) have also gained market
approval in 2014 and 2015, respectively, to treat hematological
malignancies and various solid cancer (Grasso, 2015).
Structurally, HDAC inhibitors can be classiﬁed into four
chemical groups including hydroxamates, benzamides, car-
boxylates and cyclic peptides. Among these, the hydroxamates
are still considered as the most potent HDAC inhibitors
(Kim et al., 2011). In our previous papers (Nam et al., 2013;H
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reported several series of hydroxamic acids bearing benzothia-
zole, 5-substituted phenyl-1,3,4-thiadiazole or 3-substituted-2-
oxoindoline (Fig. 2). These compounds were shown to be very
potent HDAC inhibitors and exhibited promising anticancer
effects. In continuity of our research, we have designed,
synthesized and evaluated a series of hydroxamic acids
containing 50(70)-substituted-20-oxospiro[1,3]dioxolane-2,30-in
doline system. The present paper describes the results we
obtained from this study.
2. Experimental
2.1. Materials and reagents
All the reagents and solvents used for the syntheses were pur-
chased from Aldrich or Fluka Chemical Corp. (Milwaukee,
WI, USA) or Merck and used without any further puriﬁcation.
The Fluoregenic HDAC2 Assay Kit used for enzymatic
HDAC assay was obtained commercially from BPS
Bioscience, Inc.
2.2. Physicochemical measurements
Melting points were obtained on a Gallenkamp Melting Point
Apparatus (LabMerchant, London, United Kingdom) and are
uncorrected. Infrared (IR) spectra were recorded on a Perki-
nElmer Spectrum 100 FT-IR spectrometer (PerkinElmer,
Inc., USA) and an Agilent 660 FTIR (Agilent Technologies,
Inc., USA) using KBr disk method. Electrospray ionization
(ESI-MS) spectra were obtained on a LTQ Orbitrap XLXD-101
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instrument spectrometer. Nuclear magnetic resonance
(NMR) spectra were recorded using tetramethylsilane as an
internal standard on a Bucker 500 MHz spectrometer with
DMSO-d6 used as a solvent unless otherwise indicated. Thin-
layer chromatography (TLC) was performed on Whatman
250 lm Silica Gel GF254 Uniplates and visualized under UV
light at 254 nm.
2.3. General procedure for preparation of (E)-N-hydroxy-3-
(4-((20-oxospiro[[1,3]dioxolane-2,30-indoline]-10-yl)methyl)
phenyl)propenamide derivatives
2.3.1. Synthesis of (E)-N-hydroxy-3-(4-((20-oxospiro
[[1,3]dioxolane-2,30-indoline]-10-yl)methyl)phenyl)
propenamide (4a)
2.3.1.1. Synthesis of spiro[[1,3]dioxolane-2,30-indoline]-20-one
(2a). A solution of isatin (1a, 147 mg, 1 mmol), ethane-1,2-
diol (0.56 mL, 620 mg, 10 mmol) and p-toluenesulfonic acid
(p-TsOH, 1 mmol) in 3 mL of toluene was reﬂuxed for 4 h.
After the reaction completed, the crude reaction mixture was
extracted with toluene and washed with water. The organic
layer was dried over anhydrous sodium sulfate and the solvent
was evaporated under reduced pressure to furnish the desired
compound 2a as slightly yellow solid in 86% yield.
2.3.1.2. Synthesis of (E)-methyl 3-(4-((20-oxospiro[[1,3]
dioxolane-2,30-indoline]-10-yl)methyl)phenyl)propenoate (3a).
To a solution of compound 2a (190 mg, 1 mmol) in anhydrous
dimethylformamide (DMF, 2 mL) were added K2CO3
(207 mg, 1.5 mmol) and KI (20 mg, a catalytic amount). The
resulting mixture was continuously stirred at room tempera-
ture for 30 min. Then, (E)-methyl 3-(4-bromomethyl)phenyl)
propenoate (255 mg, 1 mmol) dissolved in anhydrous DMF
(1 mL) was added dropwise into the reaction mixture, which
was again stirred at room temperature for further 24 h. The
reaction mixture was ﬁnally poured into 30 mL of ice-water.
The precipitates formed were ﬁltered and washed with water,
then dried at 60 C for 24 h to afford the desired compound
3a as yellow solid in 84% yield.
2.3.1.3. Synthesis of (E)-N-hydroxy-3-(4-((20-oxospiro[[1,3]-
dioxolane-2,30-indoline]-10-yl)methyl)phenyl)propenamide
(4a). The intermediate 3a (190 mg, 0.5 mmol) and NH2OH.
HCl (700 mg, 10 mmol) were dissolved in MeOH (4 mL) in a
round bottom ﬂask. The solution was cooled to 5 C. A solu-
tion of NaOH (800 mg, 20 mmol) in 1.5 ml of H2O was also
cooled to 0–5 C and added dropwise into the reaction ﬂask.
The mixed solution was stirred at 5 C until the starting
material was consumed completely. The reaction mixture was
acidiﬁed with HCl 5% solution to form precipitates. The crude
product was ﬁltered, dried and recrystallized fromMeOH/H2O
to give the target compound 4a as white solid in 40% yield.
Mp. 267.2–268.7 C; Rf = 0.52 (DCM/MeOH= 9/1); IR
(KBr, cm1): 3211.1 (NH), 3060.1 (CAH, arene), 2925.5,
2854.7 (CAH, CH2), 1727.9, 1666.1 (C‚O), 1618.5, 1488.7,
1468.9 (C‚C); ESI-MS (m/z): 388.9 [M + Na]+, 367.0 [M
+ H]+; 1H NMR (500 MHz, DMSO-d6, ppm): d 10.78 (1H,
s, NH), 9.10 (1H, s, OH), 7.54 (2H, d, J= 8.0 Hz, H-20, H-
60), 7.42 (1H, d, J= 15.75 Hz, H-2), 7.39 (1H, d,
J= 7.5 Hz, H-40 0), 7.35 (1H, d, J= 7.5 Hz, H-60 0), 7.31 (2H,Please cite this article in press as: Dung, D.T.M. et al., Exploration of novel 50(70)-su
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6.95 (1H, d, J= 8.0 Hz, H-70 0), 6.43 (1H, d, J= 15.75 Hz,
H-3), 4.85 (2H, s, H-70), 4.43–4.40 (2H, m, H-80 0a, H-90 0a),
4.32–4.30 (2H, m, H-80 0b, H-900b); 13C NMR (125 MHz,
DMSO-d6, ppm): 172.77, 162.75, 143.13, 137.87, 137.24,
134.25, 131.73, 127.96, 127.78, 124.83, 124.14, 123.32, 119.24,
109.52, 101.57, 65.73, 42.20. Anal. Calcd. For C20H18N2O5
(366.12): C, 65.67; H, 4.95; N, 7.65. Found: C, 65.71; H,
4.97; N, 7.64.
2.3.2. Synthesis of (E)-N-hydroxy-3-(4-((50-fluoro-20-oxospiro
[[1,3]dioxolane-2,30-indoline]-10-yl)methyl)phenyl)propenamide
(4b)
The target compound 4b was synthesized according to the gen-
eral procedures (Scheme 1) and the crude product was puriﬁed
by crystallization from MeOH/H2O. Slight yellow solid; Yield:
64%; Mp. 260.5–261.3 C; Rf = 0.41 (DCM/MeOH= 9/1);
IR (KBr, cm1): 3544.4 (OH), 3187.2 (NH), 3059.9 (CAH,
arene), 2903.8 (CAH, CH2), 1716.4, 1670.8 (C‚O), 1631.7,
1513.4, 1493.2 (C‚C); ESI-MS (m/z): 383.1 [M-H]; 1H
NMR (500 MHz, DMSO-d6, ppm): 10.76 (1H, s, NH), 9.01
(1H, s, OH), 7.54 (2H, d, J= 8.0 Hz, H-20, H-60), 7.42 (1H,
d, J= 15.75 Hz, H-2), 7.37 (1H, dd, J= 7.5 Hz, J0 = 2.5 Hz,
H-400), 7.31 (2H, d, J= 8.0 Hz, H-30, H-50), 7.22 (1H, td,
J= 9.0 Hz, J0 = 2.5 Hz, H-60 0), 6.98 (1H, dd, J= 8.5 Hz,
4.0 Hz, H-70 0), 6.42 (1H, d, J= 15.75 Hz, H-3), 4.87 (2H, s,
H-70), 4.41–4.37 (2H, m, H-800a, H-90 0a), 4.36–4.31 30 (2H,
m, H-80 0b, H-900b); 13C NMR (125 MHz, DMSO-d6, ppm):
172.55, 162.60, 157.81, 139.12, 137.71, 136.94, 134.24, 127.89,
127.71, 126.08, 126.02, 119.24, 118.00, 117.81, 112.76, 112.56,
111.18, 111.12, 101.23, 65.90, 42.25. Anal. Calcd. For C20H17-
FN2O5 (384.01): C, 62.50; H, 4.46; N, 7.29. Found: C, 62.53;
H, 4.48; N, 7.26.
2.3.3. Synthesis of (E)-N-hydroxy-3-(4-((50-chloro-20-oxospiro
[[1,3]dioxolane-2,30-indoline]-10-yl)methyl)phenyl)propenamide
(4c)
The target compound 4c was synthesized according to the gen-
eral procedures (Scheme 1) and the crude product was puriﬁed
by crystallization from MeOH/H2O. Yellow solid; Yield: 65%;
Mp: 255.7–256.2 C, Rf = 0.44 (DCM/MeOH= 9/1), IR
(KBr, cm1): 3588.1 (OH), 3280.4 (NH), 3003.6 (CAH, arene),
2905.5 (CAH, CH2), 1743.8, 1705.6 (C‚O), 1660.8, 1488.0
(C‚C); ESI-MS (m/z): 399.1 [M-H]; 1H NMR (500 MHz,
DMSO-d6, ppm): 10.78 (1H, s, NH), 9.05 (1H, s, OH), 7.55
(2H, d, J= 8.5 Hz, H-20, H-60), 7.54 (1H, s, H-40 0), 7.44 (1H,
d, J= 7.0 Hz, H-600), 7.42 (1H, d, J= 15.5 Hz, H-2), 7.31
(2H, d, J= 8.5 Hz, H-30, H-50), 7.02 (1H, d, J= 8.5 Hz,
H-700), 6.43 (1H, d, J= 15.5 Hz, H-3), 4.88 (2H, s, H-70),
4.41–4.39 (2H, m, H-80 0a, H-90 0a), 4.37–4.35 (2H, m, H-800b,
H-900b); 13C NMR (125 MHz, DMSO-d6, ppm): 172.82,
163.10, 142.34, 138.21, 137.34, 134.76, 131.92, 129.14, 128.43,
128.20, 128.12, 127.99, 126.84, 125.43, 119.75, 112.12, 102.60,
66.49, 42.76. Anal. Calcd. For C20H17ClN2O5 (400.08): C,
59.93; H, 4.28; N, 6.99. Found: C, 59.97; H, 4.25; N, 6.97.
2.3.4. Synthesis of (E)-N-hydroxy-3-(4-((50-bromo-20-oxospiro
[[1,3]dioxolane-2,30-indoline]-10-yl)methyl)phenyl)propenamide
(4d)
The target compound 4d was synthesized according to the gen-
eral procedures (Scheme 1) and the crude product was puriﬁedbstituted-20-oxospiro[1,3]dioxolane-2,30-indoline-based N-hydroxypropenamides
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4 D.T.M. Dung et al.by crystallization from MeOH/H2O. Yellow solid; Yield: 70%;
Mp: 257.6–258.5 C; Rf = 0.54 (DCM/MeOH= 9/1), IR
(KBr, cm1): 3216.1 (NH), 3050.7 (CAH, arene), 2973.4,
2855.4 (CAH, CH2), 1731.6, 1660.8 (C‚O), 1612.6, 1515.0,
1485.1 (C‚C); ESI-MS (m/z): 443.3 [M-H]+; 1H NMR (500
MHz, DMSO-d6, ppm): 10.78 (1H, s, NH), 9.05 (1H, s, OH),
7.64 (1H, s, H-40 0), 7.56 (1H, t, J= 9.5 Hz, H-600), 7.55 (2H,
d, J= 8.5 Hz, H-20, H-60), 7.43 (1H, d, J= 15.75 Hz, H-2),
7.30 (2H, d, J= 8.5 Hz, H-30, H-50), 6.96 (1H, d,
J= 8.5 Hz, H-70 0), 6.43 (1H, d, J= 15.75 Hz, H-3), 4.88
(2H, s, H-70), 4.41–4.38 (2H, m, H-80 0a, H-900a), 4.37–4.33
(2H, m, H-800b, H-90 0b); 13C NMR (125 MHz, DMSO-d6,
ppm): 172.69, 163.10, 143.89, 142.78, 138.21, 137.31, 134.78,
129.14, 128.43, 128.19, 128.14, 127.14, 119.75, 115.60, 112.60,
101.55, 66.51, 42.74. Anal. Calcd. For C20H17BrN2O5
(444.03): C, 59.93; H, 4.28; N, 6.99. Found: C, 59.97; H,
4.25; N, 6.97.
2.3.5. Synthesis of (E)-N-hydroxy-3-(4-((50-methyl-20-oxospiro
[[1,3]dioxolane-2,30-indoline]-10-yl)methyl)phenyl)propenamide
(4e)
The target compound 4e was synthesized according to the gen-
eral procedures (Scheme 1) and the crude product was puriﬁed
by crystallization from MeOH/H2O. White solid; Yield: 62%;
Mp: 247.3–248.8 C; Rf = 0.56 (DCM/MeOH= 9/1); IR
(KBr, cm1): 3473.5 (OH), 3208.7 (NH), 3028.5 (CAH, arene),
2920.8 (CAH, CH2), 1708.0 1670.2 (C‚O), 1629.8 1497.8
(C‚C); ESI-MS (m/z): 379.2 [M-H]; 1H NMR (500 MHz,
DMSO-d6, ppm): 10.80 (1H, s, NH), 9.05 (1H, s, OH), 7.53
(2H, d, J= 8.0 Hz, H-20, H-60), 7.42 (1H, d, J= 15.5 Hz,
H-2), 7.29 (2H, d, J= 8.0 Hz, H-30, H-50), 7.22 (1H, s, H-
400), 7.14 (1H, d, J= 8.0 Hz, H-70 0), 6.82 (1H, d, J= 8.0 Hz,
H-600), 6.43 (1H, d, J= 15.5 Hz, H-3), 4.82 (2H, s, H-70),
4.41–4.37 (2H, m, H-80 0a, H-90 0a), 4.32–4.28 (2H, m, H-800b,
H-900b), 2.24 (3H, s, CH3);
13C NMR (125 MHz, DMSO-d6,
ppm): 172.77, 163.45, 140.70, 137.33, 134.22, 132.64, 131.79,
127.95, 127.75, 127.67, 125.43, 124.18, 119.21, 109.75, 101.76,
65.74, 42.22, 20.42. Anal. Calcd. For C21H20N2O5
(380.14): C, 66.31; H, 5.30; N, 7.36. Found: C, 66.35; H,
5.27; N, 7.34.Please cite this article in press as: Dung, D.T.M. et al., Exploration of novel 50(70)-su
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[[1,3]dioxolane-2,30-indoline]-10-yl)methyl)phenyl)propenamide
(4f)
The targeted compound 4f was synthesized according to the
general procedure (Scheme 1) and the crude product was puri-
ﬁed by crystallization from MeOH/H2O. White solid; Yield:
45%; Mp: 245.3–246.5 C; Rf = 0.59 (DCM/MeOH= 9/1);
IR (KBr, cm1): 2959.5, 2839.2 (CAH, CH2), 1722.9 (C‚O),
1633.3, 1608.4 1487.2 (C‚C); ESI-MS (m/z): 397.3 [M-H];
1H NMR (500 MHz, DMSO-d6, ppm): 10.77 (1H, s, NH),
8.99 (1H, s, OH), 7.57 (2H, d, J= 7.5 Hz, H-20, H-60), 7.39
(1H, d, J= 15.5 Hz, H-2), 7.31 (2H, d, J= 7.5 Hz, H-30, H-
50), 7.25 (1H, s, H-40 0), 7.11 (1H, d, J= 7.5 Hz, H-70 0), 6.89
(1H, d, J= 7.5 Hz, H-60 0), 6.47 (1H, d, J= 15.5 Hz, H-3),
4.87 (2H, s, H-70), 4.43–4.39 (2H, m, H-80 0a, H-90 0a), 4.34–
4.30 (2H, m, H-80 0b, H-90 0b), 3.79 (3H, s, OCH3);
13C NMR
(125 MHz, DMSO-d6, ppm): 171.89, 162.46, 149.92, 138.41,
133.28, 132.99, 132.06, 128.79, 128.98, 127.63, 125.68, 124.34,
120.35, 110.06, 102.63, 65.74, 55.34, 43.67; Anal. Calcd. For
C21H20N2O6 (396.13): C, 63.63; H, 5.09; N, 7.07. Found: C,
63.66; H, 5.11; N, 7.09.
2.3.7. Synthesis of (E)-N-hydroxy-3-(4-((70-chloro-20-oxospiro
[[1,3]dioxolane-2,30-indoline]-10-yl)methyl)phenyl)propenamide
(4g)
The targeted compound 4g was synthesized according to the
general procedure (Scheme 1) and the crude product was puri-
ﬁed by crystallization from MeOH/H2O. Slight yellow solid;
Yield: 67%; Mp: 254.8–256.2 C; Rf = 0.46 (DCM/
MeOH= 9/1); IR (KBr, cm1): 3300.6 (OH), 3220.6 (NH),
3089.7 (CAH, arene), 2971.3, 2903.5 (CAH, CH2), 1734.9,
1684.6 (C‚O), 1617.4, 1514.4 (C‚C); ESI-MS (m/z): 399.2
[M-H]; 1H NMR (500 MHz, DMSO-d6, ppm): 7.54 (2H, d,
J= 8.0 Hz, H-20, H-60), 7.45 (1H, d, J= 7.0 Hz, H-600), 7.42
(1H, d, J= 15.75 Hz, H-2), 7.40 (1H, d, J= 7.5 Hz, H-40 0),
7.19 (2H, d, J= 8.0 Hz, H-30, H-50), 7.15 (1H, t, J= 8.0 Hz,
H-50 0), 6.43 (1H, d, J= 15.75 Hz, H-3), 5,21 (2H, s, H-70),
4.44–4.39 (2H, m, H-80 0a, H-90 0a), 4.39–4.35 (2H, m, H-800b,
H-90 0b); 13C NMR (125 MHz, DMSO-d6, ppm): 173.45,
162.34, 138.88, 138.36, 133.84, 127.85, 127.43, 126.33, 124.95,bstituted-20-oxospiro[1,3]dioxolane-2,30-indoline-based N-hydroxypropenamides
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Figure 3 Numbering for the target structures used in spectral
assignments.
Exploration of novel agents 5124.02, 119.05, 114.89, 100.46, 65.94, 43.77; Anal. Calcd. For
C20H17ClN2O5 (400.08): C, 59.93; H, 4.28; N, 6.99. Found:
C, 59.95; H, 4.27; N, 7.04.
2.4. Biological evaluation
2.4.1. Western Blot analysis
The human cancer line SW620 was lysed by treating in RIPA
buffer (50 mM Tris–Cl [pH 8.0], 5 mM EDTA, 150 mM NaCl,
1% NP-40, 0.1% SDS, and 1 mM phenylmethylsulfonyl ﬂuo-
ride) then extracted total protein. The lysates determined the
concentration of protein using a Bio-Rad protein assay kit
(Bio-Rad Laboratories Inc.). Samples were separated on
SDS-polypropenamide gels and transferred to nitrocellulose
membranes. The membranes were incubated with blocking
buffer (Tris-buffered saline containing 0.2% Tween-20 and
3% nonfat dried milk) and probed with the primary antibodies
against acetyl-histone-H3, -H4 and GAPDH. After washing,
membranes were reprobed with horseradish peroxidase-
conjugated secondary antibodies. An enhanced chemilumines-
cent protein (ELC) detection system was used to perform
detection of Western blot assay.
2.4.2. Fluorogenic HDAC2 assay
The enzymatic HDAC2 assay was based on the HADC2
enzyme and the Fluorogenic HDAC2 Assay Kit (BPS Bio-
science), carried out according to the supplier’s instruction.
Brieﬂy, HDAC2 enzymes were incubated with vehicle or
assayed samples at different concentrations for 30 min at
37 C in the presence of an HDAC ﬂuorimetric substrate.
The HDAC assay developer was added, and the ﬂuorescence
was measured using VICTOR3 (PerkinElmer, Waltham, MA,
USA) with excitation at 360 nm and 460 nm. The measured
activities were subtracted by the vehicle-treated control
enzyme activities and IC50 values were calculated using Graph-
Pad Prism (GraphPad Software, San Diego, CA, USA).
2.4.3. In vitro cytotoxicity assay
In vitro cytotoxicity assay was determined by the sulforho-
damine B (SRB) method as described in the literature
(Longo-Sorbello et al., 2006; Skehan et al., 1990). Three
human cancer cell lines including SW620 (colon cancer), PC3
(prostate cancer), and AsPC-1 (pancreatic cancer) cell lines
were obtained from a cancer cell bank at the Korea Research
Institute of Bioscience and Biotechnology (KRIBB). Cells were
seeded into 96-well plates at density of 9  103 cells/well,
incubated overnight and treated with samples for 48 h. All
compounds were dissolved in dimethyl sulfoxide (DMSO).
The IC50 values were calculated according to the Probit
method (Wu et al., 1992). The values reported of these
compounds are averages of three separate determinations.
2.4.4. Docking
AutoDock Vina program (The Scripps Research Institute, CA,
USA) (Trott and Olson, 2010) was used in the docking studies.
The initial structure HDAC2 (Lauffer et al., 2013) (complexed
with SAHA) was obtained from the Protein Data Bank (PDB)
(PDB ID: 4LXZ) and coordinates for the compounds were
generated using the GlycoBioChem PRODRG2 Server
(http://davapc1.bioch.dundee.ac.uk/prodrg/) (SchuttelkopfPlease cite this article in press as: Dung, D.T.M. et al., Exploration of novel 50(70)-su
as histone deacetylase inhibitors and antitumor agents. Arabian Journal of Chemistand van Aalten, 2004). The grid maps for docking studies were
centered on the SAHA binding site and comprised
26  26  22 points with 1.0 A˚ spacing after SAHA was
removed from the complex structure, as described previously.
AutoDock Vina program was run with eight-way multithread-
ing and the other parameters were default settings in Auto-
Dock Vina program.
3. Results and discussion
Compounds 4a–g were reached straightforward by a three-step
synthetic pathway. The ﬁrst step involved reﬂuxing the corre-
sponding isatin or isatin derivatives with excess of ethane-
1,2-diol in the presence of a catalytic amount of p-TsOH to
give the intermediates 2a–g in high yields. Nucleophilic substi-
tution of 2a–g with (E)-methyl 3-(4-bromomethyl)phenyl)pro
penoate proceeded smoothly in the presence of K2CO3 in
anhydrous DMF. The conversion was faster and more efﬁcient
when a catalytic KI was added. The ﬁnal step, a nucleophilic
acyl substitution reaction, proceeded more efﬁciently under
basic conditions and this step turned out to be the most trou-
blesome since under these conditions the hydrolysis of the ester
functional group always competed with the substitution by
hydroxylamine. Therefore, low temperature and short reaction
time needed to be appropriately controlled. The yields of the
ﬁnal steps were moderate (around 40%).
All target compounds were unambiguously determined by
careful spectroscopic analysis. 1H NMR spectra of the com-
pounds showed a typical singlet at around 4.90 ppm, which
was interpreted for two protons and attributable for a methy-
lene group (H-70) (Fig. 3). Two oleﬁnic protons (H-2, H-3)
appeared at around 6.40 and 7.30 ppm and coupled to each
other with J values of approximately 16.0 Hz, corresponding
to trans conﬁguration. Two multiplets appeared at around
4.30–4.40 ppm were typical of four protons (H-800, H-900) from
dioxolane moiety. 13C NMR spectral data of the compounds
were in good accordance with their structures, noting that
C-20 and C-60, C-30 and C-50, and C-800 and C-90 0 appeared
overlapped, respectively, in their spectra.
The synthesized compounds were ﬁrst evaluated for their
inhibitory effects on HDAC2 and cytotoxicity against three
human cancer cell lines, including SW620 (colon cancer),
PC3 (prostate cancer), and AsPC-1 (pancreatic cancer).
HDAC2 enzyme was chosen in this ﬁrst line biological evalu-
ation since it is one the key players involved in different types
of cancer (Ropero and Esteller, 2007). The results showed that
all compounds in the series 4a–g potently inhibited HDAC2
with IC50 values as low as 0.284 lM, almost comparable to
that of SAHA (IC50, 0.265 lM) a positive control (Table 1).bstituted-20-oxospiro[1,3]dioxolane-2,30-indoline-based N-hydroxypropenamides
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Table 1 HDAC2 inhibition and cytotoxicity of compounds 4a–g against some human cancer cell lines.
N
O
O
O
O
NHOH
R
5
7
.
Cpd. code R Molecular weight LogPa HDAC2 inhibition (IC50,
b lM) Cytotoxicity (IC50,
b lM)/cell linec
SW620 AsPC-1 PC-3
4a H 366.37 2.36 0.308 3.60 18.45 18.89
4b 5-F 384.36 2.51 0.284 3.30 7.28 11.50
4c 5-Cl 400.81 2.91 0.891 3.42 22.35 17.44
4d 5-Br 445.26 3.18 0.460 3.05 6.83 7.30
4e 5-CH3 380.39 2.84 0.358 3.44 7.47 12.25
4f 5-OCH3 396.39 2.23 0.870 4.62 27.25 22.70
4g 7-Cl 400.81 2.91 1.779 38.35 69.51 >100
SAHAd 264.32 1.44 0.265 1.44 7.04 5.30
a Calculated by ChemDraw 9.0 software.
b The concentration (lM) of compounds that produces a 50% reduction in enzyme activity or cell growth, the numbers represent the averaged
results from triplicate experiments with deviation of less than 10%.
c Cell lines: SW620, colon cancer; PC3, prostate cancer; AsPC-1, pancreatic cancer.
d SAHA, suberoylanilide hydroxamic acid, a positive control.
6 D.T.M. Dung et al.These HDAC2 inhibitory effects were also comparable
to those of a series of 3-oxime-2-oxoindoline-based
N-hydroxypropenamides reported by our group recently
(Dung et al., 2015). The cytotoxicity of these compounds,
however, was less potent in comparison with SAHA. The
IC50 values of these compounds in three assayed cancer cell
lines were generally higher than those of SAHA (Table 2).
Low water solubility of these compounds (as manifested by
logP values, Table 2), leading to lower cellular penetration,
among other factors, might be explainable for this disparity
between enzyme inhibitory potency and cytotoxicity. It seemed
that most of the compounds were more cytotoxic toward colon
cancer cells (SW620) than prostate (PC-3) and pancreaticTable 2 Binding afﬁnities of compounds 4a–g toward
HDAC2.
N
O
O
O
O
NHOH
R
5
7
.
Cpd. code R Molecular
weight
LogPa Binding Aﬃnity
(kcal/mol)
4a H 366.37 2.36 9.8
4b 5-F 384.36 2.51 9.9
4c 5-Cl 400.81 2.91 9.9
4d 5-Br 445.26 3.18 9.9
4e 5-CH3 380.39 2.84 9.7
4f 5-OCH3 396.39 2.23 9.9
4g 7-Cl 400.81 2.91 9.6
SAHAb 264.32 1.44 7.4
a Calculated by ChemDraw 9.0 software.
b SAHA: suberoylanilide hydroxamic acid.
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indoline ring seemed to be more favorable for both HDAC2
inhibition and cytotoxicity, as manifested by the IC50 values
of compound 4c vs. 4g (Table 2). These results have also
been observed in the series of 3-oxime-2-oxoindoline-based
N-hydroxypropenamides (Dung et al., 2015).
When analyzed by Western Blot assay, it was clearly
observed that the inhibition of histones (H3 and H4) deacety-
lation by the compounds was very well correlated with
cytotoxicity. For example, the levels of acetyl-histone-H3
and -H4 in total cell lysates in the presence of compound 4g
were not visible (Fig. 4). Compound 4g was the least cytotoxic
in the series (Table 1).
To draw some insights into the interaction of these com-
pounds with HDAC, we have implemented docking experi-
ments using the active site of HDAC. Since histone-H3 and
histone-H4 deacetylation has been shown to be principally reg-
ulated by HDAC2 and HDAC3 (Pelzel et al., 2010), we
decided to select the structure of HDAC2 in complex with
SAHA as a docking template. The crystal structure of HDAC2Figure 4 Effects of the compounds 4a–g on histone acetylation
in SW620 cells. Cells were treated with compounds or SAHA at
3 lg/mL for 24 h. Levels of acetyl-histone-H3 and -H4 in total cell
lysates were determined by Western immunoblot analysis.
bstituted-20-oxospiro[1,3]dioxolane-2,30-indoline-based N-hydroxypropenamides
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Figure 5 Stereo-view presentations of the actual binding poses of SAHA and simulated docking poses of compounds 4a–g to HDAC2.
SAHA is represented as a bold stick model with carbon, nitrogen, and oxygen atoms in pink, blue and red, respectively. Compounds 4a–g
are presented as a stick model. The most important parts for the enzyme for interaction of these compounds were shown as a stick model
with carbon, nitrogen, and oxygen colored as gray, blue and red, respectively. Zn2+ ion is shown as a bright gray sphere.
Exploration of novel agents 7in complex with SAHA (PDB ID: 4LXZ) has been reported
recently by Lauffer and co-workers (Lauffer et al., 2013). We
executed control docking experiments with SAHA to the crys-
tal structures of HDAC2 using AutoDock Vina program
(Trott and Olson, 2010) after SAHA was removed from the
complex structure, as described previously (Oanh et al.,
2011; Nam et al., 2013). It was found from docking experi-
ments that all the compounds synthesized were located in the
active site with binding afﬁnities much higher than that of
SAHA, as manifested by stabilization energies ranging from
9.9 to 9.6 kcal/mol, much lower than that of SAHA
(7.4 kcal/mol) (Table 2). It was found from the docking
experiments that, a zinc ion (gray sphere) was coordinated
by three residues of HDAC2, including Asp181, His183 and
Asp269 (Fig. 5). All compounds in series 4a–g were shown
to have very similar binding modes and these compounds
interacted with the zinc ion in a similar manner as SAHA
did. Their orientation and binding afﬁnity appeared to be
insigniﬁcantly different. For all compounds, it was found
that a central benzene ring linking the indoline and
N-hydroxypropenamide moieties was tightly stacked between
Phe155 and Phe210 residues of the enzymes (Fig. 5) and this
stacking interaction could be the key factor attributing to the
high binding afﬁnities of the compounds with HDAC2.
It was found from these docking experiments that the indo-
line part insigniﬁcantly interacted with the enzymes. Subse-
quently, very little variance in the binding afﬁnities among
the compounds with different substituted groups was
observed. These values were almost similar between the com-
pounds within the series (4a–g). Thus, these docking results
presently could not explain for the 2 to 3-fold difference
between the IC50 value of compound 4g and that of other
compounds in the HDAC2 enzyme inhibition assay (Table 1).
Similarly, it was also not possible to explain a 7-fold difference
in the IC50 value of compound 4g in comparison with that of
SAHA. To fully explain this arbitrary, a more detailed docking
protocol might need to be designed and executed.Please cite this article in press as: Dung, D.T.M. et al., Exploration of novel 50(70)-su
as histone deacetylase inhibitors and antitumor agents. Arabian Journal of Chemist4. Conclusion
In conclusion we have designed, synthesized and evaluated a
series of N-hydroxypropenamides containing 50(70)-substitu
ted-20-oxospiro[1,3]dioxolane-2,30-indoline system. The com-
pounds in this series displayed potent inhibitory effects against
HDAC2 with IC50 values as low as 0.284 lM (compound 4b),
almost comparable to those of SAHA (IC50, 0.265 lM), a pos-
itive control. In Western blot analysis, these compounds also
exhibited noted inhibition toward histone deacetylation and
this inhibition was found to correlate well with the cytotoxicity
of the compounds in three human cancer cell lines. Docking
studies indicated the compounds in this series bound to
HDAC2 with high binding afﬁnities (9.8 kcal/mol) com-
pared to SAHA (7.4 kcal/mol). Thus, the 50(70)-substituted-
20-oxospiro[1,3]dioxolane-2,30-indoline system could be used
as replacement for further design of potential HDAC
inhibitors.
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